Targeting invadopodia-mediated breast cancer metastasis by using ABL kinase inhibitors

Area of Science:

• Oncology
• Molecular Biology
• Cancer Research

Background:

• Metastatic dissemination is the primary cause of mortality in breast cancer.
• Current treatments can slow metastasis but not eradicate it.
• Invadopodia are crucial for cancer cell invasion and extracellular matrix degradation.

Purpose of the Study:

• To investigate the role of ABL kinase inhibitors in blocking breast cancer metastasis.
• To explore the mechanism by which these inhibitors affect invadopodium formation and function.
• To assess the prognostic value of Arg and cortactin in breast cancer metastasis.

Main Methods:

• Treatment of breast cancer cells with ABL kinase inhibitors (imatinib, nilotinib, GNF-5).
• Assessment of invadopodium precursor formation, cortactin phosphorylation, and actin polymerization.
• Evaluation of extracellular matrix degradation and invasion.
• Mouse xenograft model to study in vivo metastasis.
• Proteogenomic analysis of breast cancer patient databases.

Main Results:

• ABL kinase inhibitors impede invadopodium precursor formation and maturation.
• Inhibitors decrease actin polymerization, extracellular matrix degradation, and invasion.
• In vivo studies show reduced MMP activity, invasion, and lung metastasis in treated mice.
• Co-expression of Arg and cortactin correlates with distant metastasis and poor prognosis.

Conclusions:

• Therapeutic inhibition of ABL kinases effectively blocks breast cancer metastasis.
• Arg and cortactin serve as prognostic markers for metastatic dissemination.
• Targeting ABL kinases presents a promising strategy for preventing breast cancer spread.